Dr. Elliott Sigal has over 25 years of combined experience in medicine, research and executive management. Most recently, he served as director, executive vice president and chief scientific officer and president of R&D at Bristol-Myers Squibb from 2004 until 2013. Elliott was a principal architect of the company’s successful biopharma transformation strategy, with a focus on innovative therapies for unmet medical needs, and was instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in its String of Pearls initiative. Under his leadership, 14 new medicines were brought to market. Elliott previously held positions of increasing responsibility in drug discovery at the pharmaceutical company Syntex and also was vice president of R&D and chief executive officer for the genomics firm Mercator Genetics, where he provided the research leadership that resulted in the discovery of the gene for hemochromatosis, a common disorder that leads to iron overload, diabetes and liver disease.
Elliott received his M.D. from the University of Chicago and trained in internal medicine and pulmonary medicine at the University of California, San Francisco (UCSF). He received his research training at the Cardiovascular Research Institute at UCSF and served on the faculty of the UCSF department of medicine. He received his B.S., M.S. and Ph.D. in industrial engineering from Purdue University. Elliott currently serves as a member of the board of directors for the Mead Johnson Nutrition Company, the Melanoma Research Alliance and the University of California San Francisco Nina Ireland Program for Lung Health.